Premium
A comparison of hyperimmune egg protein and placebo for efficacy and safety among healthy young adults
Author(s) -
Scheett Timothy P,
Martin Tyler D.,
Carr Benjamin M.,
Koster Carolyn A.,
Celmer Patricia A.,
Whitener Jeffrey A.,
Webster Michael J.
Publication year - 2008
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.22.1_supplement.1108.1
Subject(s) - adverse effect , medicine , rash , diarrhea , vomiting , placebo , nose , nasal congestion , gastroenterology , surgery , alternative medicine , pathology
To evaluate the safety and efficacy of oral HIE supplementation during a sample training program. Twenty‐four recreationally active males (23.6 yrs, 176 cm, 69.2 kg and 17.1 % body fat) were randomly assigned to either HIE (n=12) or an egg protein placebo (PLA) group. Participants were supplemented with 4.5 g/d for 2 d, 9 g/d for 2 d and 13.5 g/d for 6 d. HIE and PLA supplements were identical in appearance and taste before and after mixing with 237 mL of milk. Subjects recorded duration and severity of adverse events in a daily log. HIE and PLA had a 100% compliance with the study protocol. 17% (n=2) of HIE and 25% (n=3) of PLA reported experiencing at least one adverse event. HIE reported experiencing adverse events for a total of 10 d as compared to 24 d for PLA. In HIE one subject reported experiencing stomach ache and diarrhea for 3 d (severity of 2 on a 10 pt scale) and another subject reported a skin rash lasting 4 d (severity of 6). In PLA one subject reported experiencing stomach ache and vomiting for 3 d and increased thirst and feeling tired/sleepy for 3 d (severity of 7 and 8, respectively). Subjects reported a runny nose (n=3) lasting 1–3 days (1–5 severity) and a cough (n=2) lasting 3 d (severity 1–5). HIE was associated with fewer adverse events of similar or lesser severity than PLA and all adverse events were minimal and transitory in nature with none requiring medical intervention. Supported by Legacy for Life, LLC, Melbourne, FL